Tokyo, July 19, 2011 (JCN Newswire) - Eisai Co., Ltd. today announced the launch of its novel anticancer agent Halaven(R) in Japan for the treatment of inoperable or recurrent breast cancer. Halaven(R) is the first novel anticancer agent to be discovered and developed by the Eisai. Having simultaneously submitted marketing authorization applications to the regulatory authorities in Japan, the United States and the European Union (EU) in March 2010, the company first launched Halaven(R) in the United States in November of the same year, and began marketing the agent in the United Kingdom, Germany and other European countries in April 2011.
